TY - JOUR
T1 - Nanozymes for Catalytic Cancer Immunotherapy
AU - Ma, Jun
AU - Qiu, Jingjing
AU - Wang, Shiren
N1 - Publisher Copyright:
Copyright © 2020 American Chemical Society.
PY - 2020/6/26
Y1 - 2020/6/26
N2 - Nanozymes are nanoparticles with enzyme-mimicking properties. With the intrinsic catalytic properties, nanozymes are endowed with merits to modulate the immunosuppression of tumor immune microenvironment (TIME), mainly through altering reactive oxygen and nitrogen species (ROS/RNS) level. Besides redox imbalance, nanozymes can modulate other features of TIME, such as hypoxia. Modulations of TIME enabled by nanozymes can improve the effectiveness and efficiency of cancer therapies, especially immunotherapy. Two types of nanozymes, metal/metal oxide nanozymes and deoxyribozymes (DNAzymes) are currently investigated in cancer immunotherapy. They either act as standalone therapeutics or synergize with other therapeutic strategies to enhance antitumor effects. This Review summarizes the common nanozymes and their enzymatic properties, their interactions with TIME, and recent achievements of using nanozymes in cancer immunotherapy.
AB - Nanozymes are nanoparticles with enzyme-mimicking properties. With the intrinsic catalytic properties, nanozymes are endowed with merits to modulate the immunosuppression of tumor immune microenvironment (TIME), mainly through altering reactive oxygen and nitrogen species (ROS/RNS) level. Besides redox imbalance, nanozymes can modulate other features of TIME, such as hypoxia. Modulations of TIME enabled by nanozymes can improve the effectiveness and efficiency of cancer therapies, especially immunotherapy. Two types of nanozymes, metal/metal oxide nanozymes and deoxyribozymes (DNAzymes) are currently investigated in cancer immunotherapy. They either act as standalone therapeutics or synergize with other therapeutic strategies to enhance antitumor effects. This Review summarizes the common nanozymes and their enzymatic properties, their interactions with TIME, and recent achievements of using nanozymes in cancer immunotherapy.
KW - DNAzymes
KW - cancer immunotherapy
KW - hypoxia
KW - immune checkpoint blockade therapy
KW - nanozyme
KW - reactive oxygen species
KW - tumor immune microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85085656989&partnerID=8YFLogxK
U2 - 10.1021/acsanm.0c00396
DO - 10.1021/acsanm.0c00396
M3 - Article
AN - SCOPUS:85085656989
SN - 2574-0970
VL - 3
SP - 4925
EP - 4943
JO - ACS Applied Nano Materials
JF - ACS Applied Nano Materials
IS - 6
ER -